The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study

Hannah E. Carter*, Diana Zannino, R. John Simes, Deborah J. Schofield, Kirsten Howard, John R. Zalcberg, Timothy J. Price, Niall C. Tebbutt

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study'. Together they form a unique fingerprint.

Medicine & Life Sciences